In addition, ALKBH5 could regulate the content of metabolites and cytokines in the tumor microenvironment during GVAX (a granulocyte-macrophage colony-stimulating factor (GM-CSF) gene-transfected tumor cell vaccine)/anti-PD-1 therapy. The gene discussed is CSF2; the disease is neoplasm.